As some of you might know I have studied the Hedgehog Pathway (Hh) which is a very important pathway in stem cells. I think that stem cell pathways will first help cancer patients and then once the technology gets proofed out it will hopefully be used in regenerative medicine. Genentech and Curis have already moved a Hh antagonist into Phase II and showed regression in metastatic cancers.
Over four (4) cycles, M marker decreased from 1.0 to 0.2. M marker had stayed at 1.0 for 1.5 years despite oral treatment with thalidomide, Revlimid, and steroids.
